Aug 17, 2023 / 12:00PM GMT
Tyler Ehler - I-Mab - Senior Director of IR
Good morning, everyone, and thank you for joining us this morning and for standing by. I'd like to take this opportunity to welcome you all to the I-Mab Biopharma midyear 2023 financial results and business update conference call. My name is Tyler Ehler, and I'm I-Mab's Senior Director for Investor Relations. (Operator Instructions)
Earlier today, we issued a press release providing a review of our financial results for the midyear ended June 30, 2023, as well as an overview of our recent corporate highlights and upcoming milestones. The press release can be accessed on the Investor Relations tab on our website at ir.i-mabbiopharma.com.
Joining me today on the call from I-Mab's senior management team are Raj Kannan, CEO; Dr. John Hayslip, Chief Medical Officer; Dr. Andrew Zhu, President and Head of R&D; and Richard Yeh, Interim CFO and COO.
Raj will provide a high-level overview of our recent achievements and upcoming milestones, and John will provide an update on our R&D progress. Richard will then provide a summary of our
Half Year 2023 I-Mab Earnings Call Transcript
Aug 17, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers